An Open Label 2-arm Study to Evaluate the Impact of Adjuvant Bevacizumab on Invasive Disease Free Survival in Triple Negative Breast Cancer
Phase 3
18 Years
N/A
18 Years
N/A
Open (Enrolling)
Both
Breast Cancer
Both
Breast Cancer
Trial Information
An Open Label 2-arm Study to Evaluate the Impact of Adjuvant Bevacizumab on Invasive Disease Free Survival in Triple Negative Breast Cancer
Inclusion Criteria:
- adult patients, >=18 years of age;
- operable primary invasive breast cancer;
- completed definitive loco-regional surgery;
- primary tumor centrally confirmed as triple negative.
Exclusion Criteria:
- locally advanced breast cancers;
- previous breast cancer history;
- clinically significant cardiovascular disease.
Type of Study:
Interventional
Study Design:
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Outcome Measure:
Invasive disease-free survival
Outcome Time Frame:
Event driven
Safety Issue:
No
Principal Investigator
Clinical Trials
Investigator Role:
Study Director
Investigator Affiliation:
Hoffmann-La Roche
Authority:
France: AFSSAPS
Study ID:
BO20289
NCT ID:
NCT00528567
Start Date:
December 2007
Completion Date:
January 2015
Related Keywords:
- Breast Cancer
- Breast Neoplasms
Name | Location |
|---|---|
| Hinsdale, Illinois 60521 | |
| New Britain, Connecticut 06052 | |
| Bettendorf, Iowa 52722 | |
| Albany, Georgia 31701 | |
| Birmingham, Alabama 35294 | |
| Fountain Valley, California 92708 | |
| Miami, Florida 33176 | |
| Columbia, Missouri 65203 | |
| Albany, New York 12208 | |
| Cleveland, Ohio 44195 | |
| Nashville, Tennessee 37203-1632 | |
| Austin, Texas 78705 | |
| Flint, Michigan 48532 | |
| McLean, Virginia 22101 | |
| Little Rock, Arkansas 72205-7199 | |
| Hackensack, New Jersey 07601 | |
| Baltimore, Maryland 21287 | |
| Charlotte, North Carolina | |
| South Burlington, Vermont | |
| Charleston, South Carolina | |
| Washington, District of Columbia |
